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| INTRODUC TI ON
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer-related deaths in men worldwide.
1 Non-smallcell lung cancer (NSCLC), a more prevalent lung cancer subtype, accounts for approximately 80%-85% of all cases. 2 Although the treatment of surgical operation, chemotherapy, radiotherapy, targeted therapy, and immunotherapy is widely carried out, only 15%
of NSCLC patients survive more than 5 years. 3 One of most important reasons behind the high incidence and low 5-year survival rate of NSCLC is the low rate of early detection/diagnosis. Therefore, the limitations of current diagnostic and treatment approaches should be considered in future work aimed at developing a more complete investigation of the underlying cellular activities or molecular mechanisms in NSCLC tumorigenesis, as these studies could provide novel biomarkers and therapeutic targets.
Advances in next-generation deep sequencing and bioinformatics technologies confirm that only 1%-2% of the human genome can encode proteins. 4 Based on their length, RNAs without coding potential are divided into two subclasses: (a) small or short non-coding RNAs; and (b) long noncoding RNAs (lncRNAs; ≥200 nt). Recent research has revealed that lncRNAs have dramatic impacts on multiple biological processes through diverse mechanisms, including translational inhibition, mRNA degradation, RNA decoys, recruiting chromatin modifiers, and regulating protein activity. 5 Interestingly, emerging evidence has revealed that aberrant lncRNA expression is involved in human diseases, especially cancers. [6] [7] [8] For instance, lncRNA TINCR promotes the proliferation of gastric cancer cells by binding to Staufen1 protein and subsequently influencing KLF2 expression and mRNA stability. 9 Furthermore, our previous studies showed that lncRNA MEG3 is significantly downregulated in lung adenocarcinoma, and partially reverses cisplatin resistance in LAD cells through p53/Bcl-xl-induced mitochondrial-directed apoptosis. 10 Additionally, LINC01234 can exert oncogenic function by serving as a competing endogenous RNA for microRNA (miR)-204-5p that regulates core-binding factor β expression in gastric cancer.
11
Actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1) is an lncRNA transcribed from the antisense DNA strand of the AFAP1 gene and was first reported to be upregulated in esophageal adenocarcinoma tissues and cell lines. 12 Further work showed that AFAP1-AS1 was upregulated in lung adenocarcinoma, gastric cancer, pancreatic ductal adenocarcinoma, cholangiocarcinoma, colorectal cancer, and nasopharyngeal carcinoma, where it was associated with progression and poor prognoses. [13] [14] [15] [16] [17] [18] [19] Previous studies also suggested that AFAP1-AS1 participated in cell proliferation, apoptosis, and invasion by regulating PTEN/p-AKT and RhoA/Rac2 signaling. 20, 21 Nevertheless, elucidating the oncogenic functions of AFAP1-AS1 in NSCLC development and progression requires further effort. Here, we investigated the effect of AFAP1-AS1 on NSCLC cell proliferation and migration in vitro and in vivo and identified novel targets and mechanisms of AFAP1-AS1, which could fully elucidate its critical role in the pathological processes of NSCLC.
| MATERIAL S AND ME THODS

| Differential expression analysis
Lung cancer gene expression data were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) dataset.
The independent datasets from GSE31210, GSE19804, GSE18842, and GSE19188 were analyzed in this study. The BAM files and normalized probe-level intensity files were downloaded from TCGA and GEO databases, respectively. The probe sequences were downloaded from GEO or microarray manufacturers, and Bowtie was used to reannotate probes according to GENCODE Release 20 annotation for lncRNAs. For multiple probes corresponding to one gene, the probe with the maximum signal was selected to generate expression of lncRNAs. The Kaplan-Meier curve was used to test lncRNA association with time to progression. For verifying expression correlation between genes, Pearson's correlation analysis was used after CEL files from GSE19804 were downloaded and normalized by Robust Multichip Average.
| Tissue sample collection
We acquired 96 pairs of lung cancer and adjacent normal tissues from patients who underwent surgery at The Second Affiliated
Hospital of Nanjing Medical University (Nanjing, China) between 2010 and 2013. Patients were diagnosed with NSCLC based on imaging examination and histopathological analysis, no preoperative adjuvant chemotherapy was undertaken before surgical operation.
All collected tissues were snap frozen in liquid nitrogen and stored at −80°C until required. Table 1 
| Cell culture
The normal human bronchial epithelial cell line (16HBE) and another five NSCLC cell lines (A549, SPC-A1, PC-9, H1299, and H1975)
were maintained in RPMI-1640/DMEM (Gibco, Grand Island, NY, USA) supplemented with 10% newborn calf serum (NBCS; PAA Laboratories, Haidmannweg, Australia ) and 1% penicillin (100 U/ mL)/streptomycin (100 μg/mL; Invitrogen, Carlsbad, CA, USA) in a 5% CO 2 and humidified atmosphere at 37°C.
| RNA extraction and quantitative PCR assays
Total RNA was isolated from tissues or cultured cells using TRIzol rea- Table S1 . Our qRT-PCR results were based on relative threshold cycle (CT) values, and then in the form of fold changes (2 −ΔΔCT ).
| RNA interference
Small interfering RNAs were transfected into PC-9 and H1975 cells using Lipofectamine 2000 (Invitrogen). We purchased three individual AFAP1-AS1 siRNAs (si-AFAP1-AS1 1#, 2#, and 3#), scrambled negative control siRNA (si-scrambled), enhancer of zeste homolog 2 (EZH2) siRNA, and lysine-specific demethylase 1 (LSD1) siRNA from GenePharma (Shanghai, China). These siRNA sequences are summarized in Table S1 . Cells were collected for experiment analysis after 48 hours of incubation.
| Plasmid generation
The pCDNA-HMG box-containing protein 1 (HBP1) vector was synthesized by subcloning the HBP1 sequence (NM_001244262) into the pCDNA3.1 vector (YouBio, Hunan, China), and pCDNA3.1 vector was used as a control group. Plasmid vectors were transfected into NSCLC cells by X-tremeGENE HP DNA transfection reagent (Roche, Basel, Switzerland).
| Cell proliferation assays
The 
| Cell migration assays
Using Transwells (8.0-μm pores; Corning, Tewksbury, MA, USA) for migration assays, 300 μL medium containing 1% NBCS and 2.5 × 10
4
NSCLC cells was transferred to the upper chamber. Medium containing 10% NBCS without cells were transferred to the lower chamber. After incubation at 37°C for 48 hours, we used cotton wool to wipe off the cells remaining on the upper membrane. The other cells that migrated to the lower membrane were fixed and stained, followed by photographing with an IX51 inverted microscope (Olympus, Tokyo, Japan).
| 5-Ethynyl-2'-deoxyuridine analysis
The 5 
| Tumor formation assay in vivo
The animal experiment protocols were approved by The Animal 
| Subcellular fractionation
Subcellular fractionation assays were carried out using the PARIS Kit (Life Technologies). According to the manufacturer's instructions, the cells can be separated into nuclear and cytoplasmic fractions before undergoing the RNA isolation procedure. 
| RNA immunoprecipitation assays
| Chromatin immunoprecipitation assays
Chromatin immunoprecipitation (ChIP) assays were carried out using 
| Immunohistochemistry
The primary tumors were subjected to immunohistochemical staining analysis of Ki-67 protein levels as previously described.
| Statistical analysis
All statistical analyses were carried out using SPSS 20.0 software (IBM, Armonk, NY, USA). The significance of differences in experimental data between different groups was estimated by Student's t test, and GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, USA) was used to draw all the plots. The correlations between AFAP1-AS1 expression and the clinical features of NSCLC patients were examined by the χ 2 test. The Kaplan-Meier method was used to draw progression-free survival and overall survival curves, and the log-rank test was applied for comparison. All tests were two-sided, and P values less than .05
were chosen for statistically significant.
| RE SULTS
| Antisense-transcribed lncRNA AFAP1-AS1 upregulated in tissues and cell lines
To identify expression levels of AFAP1-AS1 in NSCLC cancerous tissues compared with noncancerous tissues, four microarray datasets F I G U R E 1 Relative actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1) expression levels in non-small-cell lung cancer (NSCLC) tissues and its clinical relevance. A, Relative expression of AFAP1-AS1 in NSCLC cancer tissues compared with normal tissues was analyzed by using Gene Expression Omnibus datasets including GSE31210, GSE19804, GSE18842, and GSE19188. B, Relative expression of AFAP1-AS1 in lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) tissues compared with normal tissues was analyzed using The Cancer Genome Atlas dataset. C, Relative expression of AFAP1-AS1 in NSCLC tissues compared with adjacent normal tissues (n = 96) was detected by quantitative real-time PCR, and normalized to GAPDH expression. D, The patients (n = 96) were divided into two groups according to AFAP1-AS1 expression. E,F, Kaplan-Meier progression-free survival (PFS) (E) and overall survival (OS) (F) curves according to AFAP1-AS1 expression levels. G, Kaplan-Meier curves of recurrence-free survival (RFS) in LUAD patients, by using data from TCGA-LUAD. Patients were grouped by the median AFAP1-AS1 expression. Data are presented as the mean ± SEM. *P < .05, **P < .01
(GSE31210, GSE19804, GSE18842, and GSE19188) were obtained from GEO datasets. As a result, AFAP1-AS1 expression levels were upregulated in NSCLC tumor tissues ( Figure 1A) , and sequencing data from TCGA also confirmed the high expression of AFAP1-AS1 in human lung squamous cell carcinoma and human lung adenocarcinoma tissues compared with normal tissues ( Figure 1B ). In addition, we analyzed AFAP1-AS1 expression in 96 paired NSCLC and adjacent normal tissues using qRT-PCR normalized to GAPDH, and relatively high expression was found in 78 of 96 samples (fold change >1.2; Figure 1C ).
Moreover, to analyze correlations between AFAP1-AS1 expression and the clinical features of NSCLC patients, the 96 NSCLC patients were classified into two groups according to the median ratio (fold-change = 5.531) of relative AFAP1-AS1 expression in tumor tissues: (a) the high AFAP1-AS1 group (n = 48, AFAP1-AS1 expression ratio ≥5.531), and (b) the low AFAP1-AS1 group (n = 48, AFAP1-AS1 expression ratio ≤5.531) ( Figure 1D ). As indicated in Table 1 , the high AFAP1-AS1 group showed larger tumor size (P = .008), lymph node metastasis (P = .025), and a higher TNM stage (P = .024), but was not correlated with other characters including age (P = .54), sex (P = .837), histological subtype (P = .413), and smoking history (P = .306). KaplanMeier survival analysis showed that patients with high AFAP1-AS1 expression had shorter overall survival and progression-free survival times than those with low AFAP1-AS1 expression ( Figure 1E,F) .
As shown in Figure 1F , the median overall survival time for the low AFAP1-AS1 expression group was 36 ± 2.602 months, while for the high AFAP1-AS1 expression group it was only 26 ± 2.209 months;
progression-free survival times showed the same trend. Furthermore, by generating Kaplan-Meier curves of recurrence-free survival using survival data from TCGA, we found that the lung adenocarcinoma patients with high AFAP1-AS1 expression also had significantly worse recurrence-free survival (P < .05) ( Figure 1G ). Thus, dysregulation of AFAP1-AS1 is a key event involving a poor prognosis of NSCLC.
| In vitro effects of AFAP1-AS1 on proliferation, apoptosis, and cell cycle progression
To investigate the biological functions of AFAP1-AS1 in NSCLC cells, we first determined relative AFAP1-AS1 expression in the normal bronchial epithelial cell line 16HBE and five human NSCLC cell lines (H1975, PC-9, A549, SPC-A1, and H1299) by qRT-PCR. As shown in Figure 2A , PC-9 and H1975 cells had the highest relative AFAP1-AS1 expression compared with 16HBE cells. Next, we synthesized three siRNAs to knock down AFAP1-AS1 expression; si-AFAP1-AS1 1#
and 3# had higher interference efficiencies than si-AFAP1-AS1 2#
following transfection ( Figure 2B ). The CCK-8 assays indicated that the viability of PC-9 and H1975 cells with AFAP1-AS1-siRNA 1#/3# treatment was significantly reduced compared with cells transfected with scrambled siRNA ( Figure 2C) . Consistently, the colony formation abilities of NSCLC cells were impaired following transfection with si-AFAP1-AS1 ( Figure 2D ). Similar differences were confirmed in the EdU/DAPI immunostaining analysis ( Figure 2E ).
In order to determine whether cell cycle distribution and apoptosis were altered following AFAP1-AS1 knockdown in NSCLC cells, we undertook flow cytometric assays. Flow cytometric analysis revealed that PC-9 and H1975 cells transfected with si-AFAP1-AS1 1#
or 3# had higher rates of apoptosis and G 0 /G 1 cell cycle arrest compared with cells transfected with scrambled siRNA (Figure 3A,B) .
Taken together, these data indicated that AFAP1-AS1 promoted the proliferation of lung cancer cells by inhibiting apoptosis and promoting cell cycle transition.
| Downregulating AFAP1-AS1 inhibited NSCLC cell migration
Cancer cell invasion and migration play important roles during cancer onset and progression. Using Transwell assays, we found that PC-9 and H1975 cell migration was significantly impeded following AFAP1-AS1 knockdown ( Figure 3C ). 
| Xenograft mouse model shows that AFAP1-AS1 knockdown impedes tumor growth
| Underlying target of AFAP1-AS1 is HBP1
To investigate possible modulation of the sense gene AFAP1
by its antisense transcript AFAP1-AS1, we analyzed changes in Table S2 ). Differentially expressed genes were classified according to GO terms, followed by GO enrichment analysis. Our data identified biological processes that included pathways involved in cell proliferation and cell migration (P < .05, Figure 5D ). We then selected several upregulated genes that act as tumor suppressors in multiple cancers for further validation. Quantitative RT-PCR assays were carried out in both PC-9 and H1975 cells to examine levels of XAF1, DMGDH, and other related genes after knocking down AFAP1-AS1.
The results showed that AFAP1-AS1 knockdown upregulated the expression of XAF1, HBP1, and other genes in both PC-9 and H1975 cells, but no significant differences were observed in the levels of DMGDH, CPEB3, or GBP2 after H1975 cells were transfected with si-AFAP1-AS1. Among these AFAP1-AS1-regulated genes, the well-described transcriptional repressor HBP1 showed relatively higher fold-change in AFAP1-AS1-depleted H1975 cells ( Figure 5E ).Western blot assays confirmed that HBP1 protein levels were also upregulated in NSCLC cells following AFAP1-AS1 knockdown ( Figure 5F ).
We next explored whether AFAP1-AS1 led to decreased HBP1 expression through its interaction with LSD1 or EZH2 in PC-9
and H1975 cells by evaluating HBP1 mRNA levels in NSCLC cells transfected with siRNAs against LSD1 and EZH2. Interestingly, qRT-PCR results showed that downregulation of LSD1 increased HBP1 expression, whereas EZH2 knockdown did not (Figures S1B and 5G). Moreover, western blot analysis showed that silencing LSD1 led to increased HBP1 protein levels in PC-9 and H1975 cells. interaction in PC-9 and H1975 cells ( Figure 5I ). These findings indicated that AFAP1-AS1 mediated epigenetic changes of HBP1, recruiting LSD1 and resulting in HBP1 transcription repression in lung cancer cells.
| Overexpression of HBP1 inhibited NSCLC cell proliferation
To elucidate the biological role of HBP1 in NSCLC cells, we under- cancers, where it is associated with poor patient outcomes and aggressive clinicopathological features. 33, 34 These data suggested that the association between LSD1 and lncRNAs is clearly important in malignancy.
In the present study, we used RIP assays to reveal that AFAP1-AS1 directly binds to LSD1 in lung cancer cells. RNA transcriptome sequencing of AFAP1-AS1 knockdown PC-9 cells revealed increased F I G U R E 5 Actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1) interacts with lysine-specific demethylase 1 (LSD1) to regulate HMG box-containing protein 1 (HBP1) in non-small-cell lung cancer cells. A, Relative expression of AFAP1-AS1 in PC-9 and H1975 cell cytoplasm and nucleus using quantitative real-time (qRT)-PCR. GAPDH was used as a cytoplasm marker and U6 was used as a nuclear marker. B, RNA immunoprecipitation assays were undertaken in PC-9 and H1975 cells, expression levels of AFAP1-AS1 RNA was detected by qRT-PCR and presented based on the fold enrichment in LSD1, EZH2, and SUZ12 immunoprecipitates relative to IgG immunoprecipitates. C, Heatmap of gene alteration in AFAP1-AS1 knockdown PC-9 cells compared to control cells. D, Gene Ontology analysis for all genes with altered expressions between the negative control group and AFAP1-AS1 knockdown group cells in vitro. E, qRT-PCR was used to verify mRNA expression levels of tumor suppressors in scrambled siRNA and si-AFAP1-AS1 1#/3# transfected PC-9 and H1975 cells. It has two important domains including the HMG box DNA-binding
Effects of HMG box-containing protein 1 (HBP1) overexpression on PC-9 and H1975 cells in vitro. A, mRNA and protein levels of HBP1 in PC-9 and H1975 cells transfected with pcDNA-HBP1. B,C, CCK-8 and colony formation analysis were undertaken to detect cell viability. D,E, Flow cytometry were used to determine cell cycle and apoptotic rates of PC-9 and H1975 cells transfected with pcDNA-HBP1 or empty vector. F, Analysis of correlation between actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1) and HBP1 mRNA levels (Dct value compared with GAPDH) in non-small-cell lung cancer tissues (n = 20). G, Relationship between AFAP1-AS1 and HBP1 expression was analyzed in the profile of non-small-cell lung cancer patient tissue from Gene Expression Omnibus domain and an AXH domain. 35 HMG box-containing protein 1 has been found to have tumor-suppressive functions in multiple cancers. For instance, HBP1 overexpression sensitizes prostate cancer cells to radiation and increases apoptosis in prostate cancer cells. 36 In oral cancer, increased HBP1 expression is associated with decreased cell growth following N-acetylcysteine treatment. 37 In a separate study on breast cancer, Li and colleagues ascribed the decrease in HBP1 expression to miR-17-5p upregulation, promoting cell proliferation, invasion, and migration. 38 HMG box-containing protein 1 inhibits the progression from G 1 to S phase of the cell cycle by regulating several key genes involved in cell proliferation, such as CDKN2A (p16 INK4A) and CDKN1A (p21 CIP1), and also contributes to oncogenic RAS-induced senescence F I G U R E 7 Actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1) promotes non-small-cell lung cancer cell proliferation partly through negative regulation of HMG box-containing protein 1 (HBP1). A,B, CCK-8 and colony formation assays showed that si-AFAP1-AS1 and si-HBP1 cotransfection could partly reverse cell proliferation abilities of PC-9 and H1975 cells transfected with si-AFAP1-AS1. C, Western blot analysis of the level of HBP1 in PC-9 cells transfected with si-AFAP1-AS plus si-HBP1 or si-AFAP1-AS1 alone and terminal cell differentiation, supporting the hypothesis that HBP1 acts as a tumor suppressor. 39 As HBP1 mRNA/protein expression is reduced in NSCLC patients due to promoter hypermethylation, we found that HBP1 overexpression inhibited lung cancer cell proliferation and cell cycle progression and slightly induced apoptosis. 40 Finally, decreasing HBP1 expression partially reversed the inhibition of proliferation in lung cancer cells following AFAP1-AS1 knockdown. The results indicated that HBP1 acts as a tumor suppressor and its inhibition plays an important role in the malignant phenotype of NSCLC.
In conclusion, our findings showed that AFAP1-AS1 is upregulated in NSCLC tissues and cells, and that high AFAP1-AS1 expression in NSCLC patients suggests worse outcomes. Furthermore, AFAP1-AS1 can promote NSCLC cell proliferation and migration through epigenetic silencing of tumor suppressor HBP1. Our study could provide a new insight into targeting the AFAP1-AS1/LSD1/ HBP1 axis as a treatment strategy for NSCLC patients.
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